The inducible deletion of Drosha and microRNAs in mature podocytes results in a collapsing glomerulopathy  by Zhdanova, Olga et al.
see commentary on page 692
The inducible deletion of Drosha and microRNAs in
mature podocytes results in a collapsing
glomerulopathy
Olga Zhdanova1,2, Shekhar Srivastava1,3, Lie Di1,3, Zhai Li1, Leila Tchelebi1, Sara Dworkin1,
Duncan B. Johnstone4, Jiri Zavadil5,6, Mark M. Chong1,7, Dan R. Littman1,8, Lawrence B. Holzman4,
Laura Barisoni5 and Edward Y. Skolnik1,2,3
1The Helen L. and Martin S. Kimmel Center for Biology and Medicine at the Skirball Institute for Biomolecular Medicine, New York
University Langone Medical Center, New York, New York, USA; 2Division of Nephrology, Department of Internal Medicine,
New York University Langone Medical Center, New York, New York, USA; 3Department of Pharmacology, New York University Langone
Medical Center, New York, New York, USA; 4Department of Nephrology, University of Pennsylvania School of Medicine,
Philadelphia, Pennsylvania, USA; 5Department of Pathology, New York University Langone Medical Center, New York,
New York, USA; 6NYU Cancer Institute and Center for Health Informatics and Bioinformatics, New York University Langone Medical
Center, New York, New York, USA; 7The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
and 8Howard Hughes Medical Institute, New York University Langone Medical Center, New York, New York, USA
Micro-RNAs (miRNAs) are short (average 22 nucleotides)
noncoding regulatory RNAs that inhibit gene expression by
targeting complementary 30-untranslated regions of protein-
encoding mRNAs for translational repression or degradation.
miRNAs play key roles in both the function and
differentiation of many cell types. Drosha and Dicer, two
RNAase III enzymes, function in a stepwise manner to
generate a mature miRNA. Previous studies have shown that
podocyte-specific deletion of Dicer during development
results in proteinuric renal disease and collapsing
glomerulopathy (CG); however, Dicer has functions other
than the generation of miRNAs. Here we found that the
podocyte-specific deletion of Drosha results in a similar
phenotype to Dicer mutants, confirming that the Dicer
mutant phenotype is due to the loss of miRNAs. Moreover,
the inducible deletion of Drosha in 2- to 3-month-old mice
(Tet-On system) resulted in CG. Thus, continuous generation
of miRNAs are required for the normal function of mature
podocytes and their loss leads to CG. Identifying these
miRNAs may provide new insight into disease pathogenesis
and novel therapeutic targets in various podocytopathies.
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Micro-RNAs (miRNAs) are short (B22 nucleotides) non-
coding regulatory RNAs in plants and animals that inhibit
gene expression by targeting protein-encoding mRNAs for
translational repression or degradation.1,2 MiRNAs bind to
complementary sites within the 30-untranslated regions of
their target mRNAs.3,4 The generation of miRNAs starts from
transcription of large RNA precursors, termed pri-miRNAs,
from the genome by RNA polymerase II or III. Pri-miRNAs
are then processed in the nucleus into shorter sequences of
B70 nucleotides, termed pre-miRNAs, by the RNase III
enzyme Drosha and the protein Pasha complex.5–7 Pre-
miRNAs have imperfect stem-loop structure and are
transported into the cytoplasm where the RNase III enzyme,
Dicer, and its double-stranded RNA binding partner, the
human immunodeficiency virus-1 transactivating response
RNA-binding protein, excise double-stranded miRNAs of
B22 nucleotides.8,9 The miRNA joins the miRISC (miRNA-
associated multiprotein RNA-induced silencing complex).10
The mature miRNA strand is preferentially retained in the
miRISC and guides it to the target sequence.
At present, over 1000 miRNAs have been identified in
humans/mammals. Current estimates predict that B60% of
all human genes are regulated by miRNAs,11 with a single
miRNA capable of binding and regulating 4200 target
sequences. A large number of papers have now described the
functional roles for miRNAs in a number of biological
processes including cell fate and differentiation, development,
cell proliferation, and apoptosis.12–14 It is also evident that
miRNAs play critical roles in maintaining normal health and
tissue homeostasis, and changes in miRNA expression are
highly relevant to disease processes.
Recently, a number of studies have begun to address the
role of miRNAs in kidney disease.15 These studies have
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demonstrated that a number of miRNAs are expressed in the
kidney, and changes in miRNA expression may contribute to
disease.16,17 Targeted deletion of Dicer in proximal tubule
cells has been shown to protect mice from ischemic
reperfusion injury.18 In diabetic nephropathy, transforming
growth factor-b upregulation of miR-216a and miR-217 in
mesangial cells may promote their survival and hypertrophy,
whereas upregulation of miR-377 by high glucose may
contribute to mesangial cell production of fibronectin,19 and
downregulation of miR192 in proximal tubule cells may
contribute to interstitial fibrosis.19,20 Changes in miRNA
expression patterns may also contribute to hepatic and renal
cyst formation in autosomal dominant polycystic kidney
disease,21,22 and may serve as biomarkers for kidney
transplant rejection.23
In addition to the above studies, three reports have
recently shown that miRNAs may also play critical roles in
podocyte homeostasis.24–26 These studies demonstrated that
podocyte-specific deletion of Dicer led to podocyte dysregu-
lation, resulting in proteinuric renal disease and collapsing
glomerulopathy (CG) with glomerular and tubulointerstitial
fibrosis and renal failure at B6–8 weeks of age. However, in
addition to playing a critical role in miRNA biogenesis, Dicer
also has functions that are independent of miRNA biogenesis.
For example, Dicer is also critical for generating small
inhibitory RNAs derived from endogenous or exogenous
double-stranded RNA transcripts.27,28 Thus, although de-
creased expression of miRNAs in podocytes lacking Dicer has
been implicated in the development of the CG phenotype, it
is not known whether this phenotype is due solely to
the loss of miRNAs or whether miRNA-independent functions
of Dicer contribute to the phenotype. Moreover, as Dicer is
deleted in developing kidneys in these studies, it still remains to
be determined whether the inducible deletion of dicer in a fully
developed kidney also results in a similar phenotype.
To address whether the phenotype in podocyte-specific
Dicer knockouts (KOs) is due solely to miRNA-dependent
regulation of normal podocyte function, or whether other
functions of Dicer contribute to the phenotype observed, we
generated mice in which Drosha was specifically deleted in
podocytes. We found that specifically inactivating Drosha in
podocytes led to CG that was comparable with the podocyte-
specific Dicer KOs previously described. In addition, we
found that inducibly deleting Drosha in podocytes at 2
months of age also led to a CG. Thus, these findings reinforce
the critical role for miRNAs in normal podocyte biology and
suggest that identifying changes in miRNA expression in
various podocyte diseases may provide novel therapeutic
targets to treat disease.
RESULTS
Podocyte-specific deletion of Drosha results in CG that is
comparable with Dicer KOs
Droshafl/fl mice have been previously described,29 in which
exon 9 is flanked by loxP sites. Deletion of exon 9 disrupts
both the full-length Drosha and two alternately spliced forms
and results in a frameshift and the appearance of multiple
stop codons. Podocyte-specific Drosha KO mice were
generated by breeding Droshafl/fl to NPHS2-Cre; Droshafl/þ
(NPHS2-Cre mice were provided by L Holzman, University
of Michigan). Dicerfl/fl mice were provided by M McManus
(University of California, San Francisco, CA) and have been
previously described.30 Podocyte-specific Dicer KOs were
generated by crossing Dicerfl/fl to NPHS2-Cre; Dicerfl/þ .
NPHS2-Cre; Droshafl/fl mice were born at the expected
Mendelian frequency. However, NPHS2-Cre; Droshafl/fl mice
developed proteinuria at about B2 to 3 weeks of age that
progressed overtime with renal failure and death occurring
between 4 and 8 weeks of age (Figure 1 and data not shown).
NPHS2-Cre; Droshafl/þ mice containing a heterozygous
deletion of Drosha in podocytes were phenotypically normal
and did not develop proteinuria or histological evidence of
kidney disease up until 12 months of age.
Histological examination of NPHS2-Cre; Droshafl/fl mice
until postnatal day 14 revealed normal glomeruli with no
apparent abnormality in glomerular development by either
light or electron microscopy (data not shown). However,
significant glomerular pathology became apparent after
postnatal day 14 that progressed over time. At 3 weeks of
age, kidneys from NPHS2-Cre; Droshafl/fl mice were smaller
and paler when compared with NPHS2-Cre; Droshaþ /þ
kidneys. Extensive foot process effacement and mild wrink-
ling of the glomerular basement membranes on electron
microscopy was the earliest pathologic finding and coincided
with the onset of proteinuria (Figure 2b, early). Histopatho-
logical examination of NPHS2-Cre; Droshafl/fl kidneys by
periodic acid-Schiff stain between 2 and 3 weeks of age
revealed only very focal collapsing changes (affecting B10%
of the total number of glomeruli), and rare (0.5–1þ ) cystic
dilatation of tubules as well as microcysts, which contained
protein casts in the lumen.
At 4–6 weeks of age, kidneys from NPHS2-Cre; Droshafl/fl
mice demonstrated extensive CG, with extensive segmental
and/or global collapse of the glomerular tuft coupled with
marked extracapillary proliferation (Figure 2a and Tables 1
and 2). Pseudocrescent formation was found in B45% of
glomeruli and segmental or global sclerosis was seen in 28%
of the total number of glomeruli, indicating progression of
the disease. Simultaneously, the remaining parenchyma was
also remarkable for extensive microcyst formation (3þ )
(Figure 2a and Tables 1 and 2). On ultrastructural analysis,
collapsing features were more severe and complete occlusion
of the glomerular capillary lumina by severe collapse of the
glomerular basement membranes could be appreciated,
together with extensive podocyte injury with the loss of
primary and secondary foot processes (Figure 2b, advanced).
These changes were proportional to the extent and duration
of proteinuria. Similar pathology was found in kidneys from
NPHS2-Cre; Dicerfl/fl mice (Tables 1 and 2 and Figure 2a and
b), although kidneys from NPHS2-Cre; Droshafl/fl mice
exhibited more severe disease at younger age (data not
shown).
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Deletion of Drosha in podocytes leads to podocyte
dedifferentiation and loss of the podocyte-specific markers
synaptopodin, Wilms’ tumor-1 (WT-1), podocin, and nephrin
CG is associated with podocyte dedifferentiation and loss of
podocyte-specific markers. Podocytes from NPHS2-Cre;
Droshafl/fl mice exhibited loss of synaptopodin and WT-1,
which was first noted at the onset of proteinuria and
progressed over time as the kidney disease progressed
(Figure 3 and Table 3). Similar findings were found in
kidneys from NPHS2-Cre; Dicerfl/fl mice (Figure 3 and
Table 3), with the exception that WT-1 expression was lost
at an earlier age in NPHS2-Cre; Droshafl/fl mice, which is
consistent with kidneys from NPHS2-Cre; Droshafl/fl mice
exhibiting a more severe phenotype at an earlier age (data not
shown).
Podocin and nephrin expression were examined by
immunofluorescent staining in NPHS2-Cre; Droshafl/fl mice
of different ages to further characterize the temporal course
of podocyte injury. The glomeruli of NPHS2-Cre; Droshafl/fl
mice with minimal changes of CG (age 2 weeks) showed
near-normal levels of nephrin and podocin expression when
compared with wild-type animals (Figure 4a and b),
indicating that podocyte development is normal in NPHS2-
Cre; Droshafl/fl mice. However, at 5–6 weeks of age when
NPHS2-Cre; Droshafl/fl mice have severe CG, levels of both
nephrin and podocin were significantly reduced in glomeruli
of NPHS2-Cre; Droshafl/fl mice. Nephrin and podocin also
displayed a disorganized and granular pattern of distribution
in NPHS2-Cre; Droshafl/fl mice that could also be appreciated
in glomeruli with early podocyte injury (Figure 4a and b).
Deletion of Drosha in podocytes leads to increased podocyte
proliferation and apoptosis and upregulation of desmin and
smooth muscle actin (SMA)
Tissue injury in a number of different cell types is frequently
associated with increased expression of intermediate filament
proteins.31 In podocytes, the intermediate filament protein
desmin is upregulated in a number of experimental models of
podocyte injury.32–34 Desmin is also upregulated in glomeruli
in NPHS2-Cre; Droshafl/fl mice, which is consistent with
significant podocyte damage in these mice. Desmin-positive
cells were primarily localized to proliferating cells (Ki-67
positive) in the urinary space, which were likely podocytes
because they also stained for the podocyte-specific marker
nestin35 (Figure 5 and Table 3). Quantification of podocyte
proliferation in NPHS2-Cre; Droshafl/fl mice demonstrated an
increase in the proliferative index (PI) in epithelial cells in the
urinary space (Table 4, PI in NPHS2-Cre; Droshafl/fl mice (4–6
weeks)¼ 0.656 (range 0.261–0.753); PI in NPHS2-Cre;
Droshafl/fl mice (2 weeks)¼ 0; PI in NPHS2-Cre; Droshaþ /þ
mice¼ 0). In addition, SMA was also upregulated in
glomeruli of NPHS2-Cre; Droshafl/fl mice (Figure 5a).
Although early on in disease SMA is most prominently
localized periglomerularly (data not shown), in advanced
disease cells in the urinary space stained prominently for
SMA (Figure 5a). Podocytes from NPHS2-Cre; Droshafl/fl also
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Figure 1 |NPHS2-Cre; Droshafl/fl develop proteinuria and renal
failure. (a) Protein concentration in urine obtained from wild-type
(WT; NPHS2-Cre; Droshaþ /þ ), heterozygous (NPHS2-Cre;
Droshafl/þ ), and homozygous Drosha (NPHS2-Cre; Droshafl/fl),
and Dicer (NPHS2-Cre; Dicerfl/fl) mutants determined by Bradford
assay (n¼ 5 mice in each group). Differences in protein
concentrations were statistically significant for homozygous
Drosha and Dicer mice when compared with WT and
homozygous animals (*Po0.05). (b) From 4-week-old WT and
homozygous Drosha mutants, 10 ml of urine was separated by
sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoreses
(10%) followed by Coomassie staining. Bovine serum albumin
(BSA) was run as a control. (c) Blood urea nitrogen (BUN)
concentration was determined in 4-week-old WT and
homozygous Drosha and Dicer mutants (n¼ 5 mice in each
group). BUN values were statistically significant in homozygous
Drosha and Dicer mice when compared with WT mice (*Po0.05).
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Figure 2 |NPHS2-Cre; Droshafl/fl develop collapsing glomerulopathy with focal glomerulosclerosis with pseudocrescents and
microcystic dilatation of tubules. (a) Histological examination (periodic acid-Schiff (PAS) stain) of kidneys from wild-type (WT; NPHS2-Cre;
Droshaþ /þ ) and homozygous Drosha (NPHS2-Cre; Droshafl/fl) and Dicer (NPHS2-Cre; Dicerfl/fl) mutants at 4 to 5 weeks of age. Upper panel,
original magnification  20 (A–C); lower panel, original magnification  40 (D–F). (b) Electron microscopy of kidneys from WT (A) or
homozygous Drosha and Dicer mutants at 2 weeks (early disease B, D) or 4 to 5 weeks (advanced disease C, E) of age. Arrows indicate
normal podocyte foot processes. Arrowheads indicate effaced podocyte foot processes. Asterisks indicate collapsed glomerular basement
membrane. Insert in panel A shows normal podocyte foot processes. Insert in panel B shows effaced podocyte foot processes.
Table 1 | Histological analysis between 4 and 6 weeks of age
Genotype/phenotype % Segm sclerosis % Segm collapse % Global sclerosis % Global collapse Tubular microcysts
NPHS2-Cre; Drosha+/+ 0 0 0 0 0
NPHS2-Cre; Droshafl/fl 14.5 14.8 12.7 29.9 3+
NPHS2-Cre; Dicerfl/fl 9.3 14.8 26.3 22.9 3+
Global collapse: global wrinkling and folding of the glomerular basement membranes with hypertrophy and hyperplasia of overlying podocytes filling the urinary space;
Global sclerosis: global solidification of tuft; Segmental collapse: segmental wrinkling and folding of the glomerular basement membranes with hypertrophy and hyperplasia
of overlying podocytes; Segmental sclerosis: segmental solidification of the glomerular tuft with adhesion to the Bowman’s capsule; Tubular microcysts: defined as dilated
tubules containing hyaline casts. The amount of microcysts is calculated on a semiquantitative scale from 0 to 3+ (0=no cysts;±=o10 cysts total at  40; 1+=1–3 cysts in at
least 5 fields at  40; 2+=4–10 cysts in at least 5 fields at  40; 3+=411 cysts in at least 5 fields at  40).
Table 2 | Characterization of renal disease in NPHS2-Cre; Droshafl/fl and NPHS2-Cre; Dicerfl/fl mice
NPHS2-Cre; Drosha+/+ NPHS2-Cre; Droshafl/fl NPHS2-Cre; Dicerfl/fl
Proteinuria  +++ +++
Glomerular sclerosis and collapsea 0% 71.9% 73.4%
Tubular microcystsa 0 3+ 3+
Podocyte phenotypeb Normal Abnormal Abnormal
Foot process effacement 0% 100% 100%
Primary processes Present Absent Absent
aSee Table 1 legend for details.
bDetails of podocyte phenotype with regard to podocin, nephrin, synaptopodin, Wilms’ tumor, ki-67, smooth-muscle actin, desmin, and nestin are discussed in the text and
shown in Figures 3, 4, 5 and Table 3.
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Figure 3 |Podocytes from Drosha and Dicer mutants have decreased expression of synaptopodin and Wilms’ tumor-1 (WT-1).
Immunohistochemistry of histological sections from 4- to 5-week-old wild-type (WT), Drosha, and Dicer mutants immunostained with
antibodies to synaptopodin and WT-1. Podocyte expression of synaptopodin and WT-1 are decreased in both Drosha and Dicer mutants.
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exhibited increased apoptosis compared with wild-type
animals and the increase in apoptosis increased with time
as CG became more advanced (Figure 5b).
Conditional inducible deletion of Drosha in podocytes at
2 months of age also results in a CG
In order to determine whether miRNAs are required for the
normal function of mature podocytes, a Tet-On system
was utilized to specifically delete Drosha in podocytes
in 2-month-old animals. Droshafl/fl; podocin-rtTATg/þ ;
tetO-CreTg/þ mice were either administered or not adminis-
tered doxycycline at 2 months of age and kidneys were
analyzed 1 month later. Previous studies have demonstrated
specific deletion of the gene of interest in 80% of podocytes
in these mice using a Z/EG reporter.36 We have also
confirmed specific deletion of exon 9 of the Drosha gene in
glomeruli isolated only from mice given doxycycline
(Figure 6a). As expected, kidneys sections were normal in
animals not exposed to doxycycline (Figure 6c, A and C), and
these mice did not develop proteinuria (Figure 6b). In contrast,
Droshafl/fl; podocin-rtTATg/þ ; tetO-CreTg/þ mice administered
doxycycline developed proteinuria beginning B2 weeks after
starting doxycycline (Figure 6b), which on histological
examination revealed a phenotype that was very similar to
the phenotype observed in the conditional KOs shown in
Figure 2. Kidneys from mice administered doxycycline for 1
month had numerous tubular microcysts accompanied by a
dense interstitial inflammation (Figure 6b, B), which on higher
magnification revealed shrunken glomeruli, with collapsed
capillary walls and proliferation of epithelial cells that filled the
urinary space (Figure 6b, D). Thus, these results demonstrate
that miRNAs are required for the maintenance of normal
podocyte function and suggest that primary changes in specific
miRNAs may contribute to disease.
In order to begin to identify candidate miRNAs that are
critical for normal podocyte function, glomeruli were
isolated by laser capture microscopy from Droshafl/fl;
podocin-rtTATg/þ ; tetO-CreTg/þ and Droshafl/þ ; podocin-
rtTATg/þ ; tetO-CreTg/þ 4 weeks following administration of
doxycycline, and miRNA expression was quantitated by
Taqman low density micro arrays (Applied Biosystems by Life
Technologies, Carlsbad, CA). These experiments identified 10
miRNAs that were consistently undetectable in mice in which
Drosha was conditionally inducibly deleted in podocytes
when compared with heterozygote animals (Figure 7).
DISCUSSION
In this study we demonstrate that conditional deletion of
Drosha in podocytes results in CG that is similar to three
previous reports that studied mice with a conditional
deletion of Dicer in podocytes.24–26 Although both Drosha
and Dicer have been shown to function in series to generate a
mature miRNA, both RNAase molecules have distinct
functions. For example, it is now appreciated that Dicer also
plays a role in processing pseudogene-derived double-
stranded RNAs into small inhibitory RNAs in mam-
mals.27,28,37 Thus, it remained a possibility that the kidney
phenotype in podocyte-specific Dicer KOs was contributed
by other functions of Dicer. Moreover, whether Dicer and by
extension miRNAs are critical for function of fully differ-
entiated mature podocytes was not addressed in these
previous studies. Our findings reported here when taken
together reinforce the importance for miRNAs in podocyte
homeostasis and/or development, and demonstrate for the
first time that mature podocytes require the continued
expression of miRNAs for normal function.
Conditional deletion of Drosha in podocytes resulted in a
kidney lesion with many of the hallmarks of CG.38,39 The
earliest phenotype observed was foot process effacement on
electron microscopy, which was accompanied by proteinuria.
As the disease progressed, podocytes underwent dediffer-
entiation, leading to the loss of expression of podocyte-
specific genes such as podocin, nephrin, synaptopodin, and
WT-1. These changes were accompanied by glomerular tuft
collapse, wrinkling of the basement membrane, and pseudo-
crescent formation, which ultimately led to renal failure and
death in most mice by 6 weeks of age.
One of the hallmarks of CG is the accumulation of
proliferating epithelial cells in Bowman’s space.38–41 This is in
contrast to other podocyte diseases, such as focal segmental
glomerular sclerosis, which is associated with podocyte loss
and lack the proliferative component seen in CG. Consistent
with the histological features of CG, NPHS2-Cre; Droshafl/fl
mice also had marked epithelial cell proliferation in
glomeruli as assessed by Ki-67 staining. One of the
controversies has been whether the proliferating cells in CG
derive from dedifferentiated podocytes or the parietal
epithelial cells that line the urinary space.42–46 Lineage-
tracing experiments have provided support for the contribu-
tion of both cell types to the proliferating epithelial cells in
Bowman’s space, depending upon the model studied.42,43,46,47
Our finding thatB80% of the proliferating epithelial cells in
NPHS2-Cre; Droshafl/fl mice express the podocyte-specific
marker nestin as well as desmin suggests that the majority of
cells in the urinary space that form pseudocrescents are
podocytes in origin. This would be in agreement with the
podocyte lineage-tracing experiments by Moeller et al.45,47 as
well as studies by Thorner et al.35 While the mechanism
whereby podocyte injury predisposes to the formation of
Table 3 | Podocyte phenotype—immunohistochemical
analysis
NPHS2-Cre;
Drosha+/+
NPHS2-Cre;
Droshafl/fl
NPHS2-Cre;
Dicerfl/fl
Synaptopodin +  
WT-1 +  
Nestin + + +
SMA  + +
Desmin  + +
Ki-67  + +
Abbreviations: , Negative staining; +, positive staining; SMA, smooth muscle actin;
WT-1, Wilms’ tumor-1.
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Figure 4 | Expression of podocin and nephrin in wild-type (WT) and Drosha mutants. Immunofluorescence of histological sections from
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pseudocrescents derived predominantly from podocytes or
parietal epithelial cells is still unknown, these findings raise
the possibility that specific miRNAs in podocytes are critical
to maintaining podocytes in a nonproliferative differentiated
state. Thus, loss of specific miRNAs in some diseases that
affect podocytes may be one of the factors that determine
whether podocytes are able to undergo a phenotypic switch
that allows them to contribute to pseudocrescent formation.
This is consistent with the known functions of miRNAs in
other cell types. For example, it has been shown that miR-1
and miR-206 play critical roles in skeletal muscle differentia-
tion by maintaining skeletal muscle in a quiescent state.48,49
Epithelial cells derived from NPHS2-Cre; Droshafl/fl mice
express the intermediate filament desmin and a-SMA.
Although desmin has been shown to be upregulated in
damaged podocytes,33,34 our finding that desmin-positive
cells in NPHS2-Cre; Droshafl/fl mice also express SMA raises
the possibility that these cells are undergoing a type 2
epithelial-mesenchymal transition (EMT),50,51 which con-
tributes to glomerular fibrosis and renal failure. EMT is not
an easy diagnosis to make in vivo, as currently there is not a
single specific change that marks this transition. Rather, it has
now been proposed that analyzing changes in expression of a
number of different markers, including cytoskelatal proteins,
transcription factors, matrix proteins, cell surface receptors,
and miRNAs, are required to identify cells undergoing
EMT.50 So far, we have been unable to demonstrate
expression of some other markers of EMT in these cells,
such as snail and b-catenin. Nevertheless, the finding that
previous studies have shown that podocytes may undergo
EMT in vitro,52 together with the finding that miRNAs
regulate EMT in other cells,53 suggests that future studies
should address whether podocytes undergo EMT in vivo and,
if so, whether miRNAs play a role in this process.
One of the new findings reported here is that inducible
conditional deletion of Drosha in podocytes at 2 months of
age led to a rapid CG with proteinuria detected after o2
weeks after being treated with doxycycline. This finding not
only supports the critical role for miRNAs in the main-
tenance of normal function of the mature podocyte, but also
strongly supports the idea that primary changes in specific
miRNAs in the various podocytopathies may directly mediate
disease. Identifying these miRNAs and the genes they regulate
will likely provide new insight into disease pathogenesis as
well as novel therapeutic targets.
MATERIALS AND METHODS
Mice
Podocyte-specific Drosha KOs were generated by crossing NPHS2-
Cre transgenic mice with mice containing a conditional allele of
Droshafl. Droshafl contains two loxP sites that flank exon 9.29
NPHS2-Cre has been shown to be activated specifically in podocytes
using a Rosa26 reporter.54 Mice were genotyped by PCR using tail
DNA and primer pairs as previously reported.29,54
Podocyte-specific Dicer KOs were generated using a similar
strategy by crossing NPHS2-Cre transgenic mice with mice contain-
ing a conditional allele of Dicerfl. Dicerfl mice have been previously
reported and were a generous gift of M McManus (University of
California, San Francisco).30
Both Drosha and Dicer mice were backcrossed onto a C57BL/6
genetic background for eight generations.
Histology
Mice were perfused with 4% paraformaldehyde through the heart.
Kidneys were then either embedded in OCT and snap frozen or fixed
in 4% paraformaldehyde overnight followed by embedding in
paraffin. Periodic acid-Schiff staining was performed on 4 mm
paraffin sections according to a standard protocol.55
Immunohistochemistry
Paraffin sections were immunostained using the antibodies
described below and detected using the avidin-biotin immunoper-
oxidase technique (Vector Laboratories, Burlingame, CA) or
fluorescent antibodies as previously described.41
Antibodies
The antibodies used in these studies were: anti-SMA (clone 1A4;
Sigma, St Louis, MO), anti-synaptopodin (clone G1D4; Progen
Biotechnik, Heidelberg, Germany), anti-WT-1 (Santa Cruz Bio-
technology, Santa Cruz, CA), anti-desmin (clone D33; Dako,
Carpenteria, CA), anti-nestin (clone 2Q178; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), anti-ZO1, Alexa Fluor 594 goat anti-rabbit
IgG, and Alexa Fluor 488 goat anti-mouse immunoglobulin
(Invitrogen, Carlsbad, CA). Anti-podocin anti-nephrin antibodies
are rabbit polyclonal antibodies that have been previously described.
Electron microscopy
Kidney cortex was sliced into 1 mm3 cubes, fixed in 2%
glutaraldehyde solution, and then processed using a standard
protocol.
Proteinuria and blood urea nitrogen determination
Urine was collected and protein concentration was determined
using the Bradford protein assay (Bio-Rad, Hercules, CA),56 as well
as by the separation of unconcentrated urine by sodium dodecyl
Figure 5 |Pseudocrescents stain positive for desmin, nestin, smooth muscle actin (SMA), and Ki-67. (a) Immunohistochemistry of
histological sections from 4- to 5-week-old wild-type (WT; NPHS2-Cre; Droshaþ /þ ), homozygous Drosha (NPHS2-Cre; Droshafl/fl), and Dicer
(NPHS2-Cre; Dicerfl/fl) mutants immunostained with antibodies as indicated. (b) NPHS2-Cre; Droshafl/fl demonstrate increased apoptosis as
collapsing glomerulopathy (CG) becomes more advanced. Statistically significant for 4- and 6-week-old NPHS2-Cre; Droshafl/fl when
compared with WT animals or 2-week-old NPHS2-Cre; Droshafl/fl (*Po0.05).
Table 4 | Proliferative index of epithelial cell in urinary space
Glomeruli with Ki-67+ cells in urinary space per
total number of collapsed glomeruli (range)
NPHS2-Cre; Drosha+/+ 0
NPHS2-Cre; Droshafl/fl (2
weeks)
0
NPHS2-Cre; Droshafl/fl
(4–6 weeks)
0.656 (0.261–0.753)
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sulfate-polyacrylamide gel electrophoresis followed by staining with
Coomassie. Blood urea nitrogen concentration on serum was
determined using the QuantichromTM urea assay kit (BioAssay
Systems, Hayward, CA).
Podocyte proliferation
Paraffin sections (4 mm) were stained with an antibody to Ki-67
(Dako). The PI was determined by counting the number of
glomeruli with Ki-67-positive cells in the urinary space per total
number of glomeruli as described in Table 4.
Apoptosis
TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling)
staining was performed with the DeadEnd Fluorometric TUNEL System
as per the manufacturer’s directions (Promega, Madison, WI). The
number of TUNEL-positive cells per 100 glomeruli was counted in
sections from three control and three mutant kidneys from each group.
Generation of conditional inducible deletion of Drosha in
podocytes
Droshafl/fl mice described above were crossed to transgenic mice
expressing both the reverse tetracycline transactivator (rtTA) under
the control of the podocyte-specific podocin promoter NPHS2
(podocin-rrTA) and the cre recombinase driven by a minimal
cytomegalovirus promoter downstream of tet operon sequences. Cre
was then induced in 8-week-old mice (Droshafl/fl; podocin-rtTATg/þ ;
tetO-CreTg/þ ) by supplementing doxycyline (4 mg/ml) to the
drinking water for 1 to 2 weeks as previously described.36 Animals
were killed 4 weeks after the administration of doxycycline and kidneys
were analyzed as described above. Droshafl/fl; podocin-rtTATg/þ ;
tetO-CreTg/þ not administered doxycycline served as controls.
Laser capture microdissection and RNA extraction
To isolate glomeruli, laser capture microdissection was performed
with PixCell II (Arcturus Bioscience Applied Biosystems by Life
Technologies). Frozen kidney sections (4mm) were dehydrated in
graded ethanol solutions, stained with hematoxyin and eosin, placed
in xylene, and air dried. Laser capture was performed under direct
microscopic visualization by melting of selected regions onto a
thermoplastic film mounted on optically transparent LCM caps
(Arcturus Engineering, Mountain View, CA). The PixCell II LCM
System (Arcturus Engineering) was set to the following parameters:
7.5 mm laser spot size, 60 mW power, and 15.0 ms duration. The
thermoplastic film containing the microdissected glomeruli was
MWMa
b
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C D
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2000 bp
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Figure 6 |Conditional inducible deletion of Drosha in
podocytes in 2-month-old animals results in a collapsing
glomerulopathy. (a) Glomeruli were isolated from Droshafl/fl;
podocin-rtTATg/þ ; tetO-CreTg/þ mice that were either administered
or not administered doxycycline and deletion of exon 9 was
assessed by PCR using primers that flank the loxP site. Deletion of
exon 9 results in a product of 334 base pairs, in contrast to the
2.5 Kb product in the wild-type gene. As molecular weight marker
(MWM), 1 kB plus Invitrogen was used. (b) Urine (10ml)
from Droshafl/fl; podocin-rtTATg/þ ; tetO-CreTg/þ mice that were
administered or not administered doxycycline for 2–4 weeks were
separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel
electrophoreses (10%) followed by Coomassie staining. Bovine
serum albumin (BSA) was run as a control. (c) Droshafl/fl; podocin-
rtTATg/þ ; tetO-CreTg/þ mice were either administered or not
administered doxycycline at 2 months of age and kidneys were
analyzed 1 month later. Shown are periodic acid-Schiff (PAS)
stains of kidneys sections from (A, C) Dox– and (B, D) Doxþ
animals. Normal glomeruli and unremarkable tubule–interstitium
( 20) is shown in A. On higher magnification (C,  40), glomeruli
are normal in size and cellularity and mesangium is normally
expanded. Glomerular basement membranes are also
unremarkable. No proliferation in the urinary space is noted. In
contrast, animals fed doxycycline (B,  20) had numerous tubular
microcysts and a dense interstitial inflammation, which on higher
magnification (D,  40) revealed shrunken glomeruli, with
collapsed capillary walls and proliferation of epithelial cells that
filled the urinary space.
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incubated with 50 ml extraction buffer and total RNA was extracted
as per the manufacturer’s instructions (PicoPure RNA Isolation Ki,
KIT0204; Arcturus). To eliminate potential genomic DNA contam-
ination, RNA samples were treated with RNAse-free DNase. RNA
concentration was measured by nanodrop and quality assessed by
bioanalyzer.
Quantitative-real time PCR profiling on TLDA arrays. Rodent
TaqMan Low Density Array (TLDA) plate A and B version 2
microfluidics cards (Applied Biosystems) were used to assess the
miRNA profiles. The contents of the TLDA A card comprised a total
of 343 miRNAs. Experimental samples from three independent mice
were profiled by ABI Prism 7900HT Sequence Detection System and
miRNA levels were normalized to the average of U6 and U87
controls contained on the plate. The array data were analyzed by
SDS software (Applied Biosystems) using the RQ¼ 2.0DDCT
method, visualized in Agilent Genespring GX11 software (Santa
Clara, CA) where they were filtered on flag calls, and then analyzed
for reproducibly modulated profiles.
Verification of Drosha deletion in podocytes
Glomeruli were isolated from 2-month-old NPHS2-Cre; Droshafl/fl
mice that were either untreated or treated with doxycyline for
2 weeks. Glomeruli were then isolated using Dynabeads as previously
described,57 yielding a population of 490% glomeruli. PCR was
then performed on glomerular DNA using primers flanking the loxP
sites (Drosha-F 50-GCAGAAAGTCTCCCACTCCT-30, Drosha-R-KO
50-AACAACTGGGGCTGAAGAGA-30), which detect deletion of
exon 9 in the Drosha gene.
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Figure 7 |Micro-RNA (miRNA) expression in glomeruli from Doxycycline– and Doxycylineþ animals. The 2-month-old Droshafl/fl;
podocin-rtTATg/þ ; tetO-CreTg/þ mice were either administered or not administered doxycycline for 2 weeks and glomeruli were isolated by
laser capture microdissection as described in the Materials and Methods section. RNA was then reversed transcribed and miRNA expression
was quantitated using Taqman Low Density Microarrays (Applied Biosystems). Shown are 10 miRNAs that were consistently markedly
downregulated in doxycycline-treated animals from three independent experiments.
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